Taysha Gene Therapies Announces $200 Million Public Offering
Taysha Gene Therapies, Inc. has priced a public offering of about 46.9 million shares at $2.75 each, with a goal of raising $200 million in gross proceeds.
Details of the Offering
The public offering includes approximately 46,868,687 shares of common stock and pre-funded warrants for about 25.9 million shares, priced at $2.749 each. The expected closing date is May 30, 2025. The company has given underwriters the option to buy an additional 10.9 million shares. This offering aims to support AAV-based gene therapies for severe monogenic diseases, particularly its lead program targeting Rett syndrome. The transaction is managed by Jefferies, BofA Securities, Piper Sandler, and Barclays, with further details available through the SEC.
Potential Positives
- This offering can provide significant funding for ongoing research and development initiatives.
- Expected gross proceeds of approximately $200 million will enhance financial resources for gene therapy programs, particularly TSHA-102.
- Underwriters have a 30-day option to purchase an additional 10,909,090 shares, potentially increasing funds raised.
- Focus on developing transformative medicines addresses serious unmet health needs, potentially enhancing investor and partner interest.
Potential Negatives
- Pricing at $2.75 may suggest market pressure or diminishing confidence in the company’s stock value, risking dilution for existing shareholders.
- The public offering could raise concerns about Taysha’s financial health and ability to fund ongoing research.
- The size of the offering—nearly 47 million shares—may overwhelm the market, adversely affecting stock performance post-offering.
FAQ
What is the public offering by Taysha Gene Therapies?
The company has announced a public offering of 46,868,687 shares priced at $2.75 each.
How much gross proceeds is Taysha expected to raise?
The expected gross proceeds are approximately $200 million before any deductions.
Who are the underwriters for this offering?
Underwriters include Jefferies, BofA Securities, Piper Sandler, and Barclays.
When is the expected closing date for the offering?
The offering is set to close on or around May 30, 2025, pending customary closing conditions.
Where can I find the prospectus for this offering?
The prospectus will be available on the SEC’s website at www.sec.gov and will be filed with the SEC.
$TSHA Hedge Fund Activity
In the latest quarter, 62 institutional investors increased their holdings in $TSHA stock, while 69 reduced theirs. Here are notable activities:
- RTW INVESTMENTS, LP added 10,115,236 shares (+116.6%), worth approximately $14,060,178.
- OCTAGON CAPITAL ADVISORS LP decreased holdings by 8,025,000 shares (-76.8%), worth about $11,154,750.
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed all 5,000,000 shares (-100.0%), valued at $6,949,999.
- POINT72 ASSET MANAGEMENT, L.P. increased their position by 4,569,678 shares, valued at $6,351,852.
- STATE STREET CORP cut their holdings by 3,240,855 shares (-50.1%), worth approximately $4,504,788.
- VR ADVISER, LLC eliminated all 3,225,180 shares (-100.0%), estimated at $4,483,000.
- JPMORGAN CHASE & CO reduced their stake by 1,640,688 shares (-62.1%), worth about $2,280,556.
Full Release
DALLAS, May 28, 2025 (GLOBE NEWSWIRE) — Taysha Gene Therapies, Inc. (Nasdaq: TSHA) announced the pricing of an underwritten public offering of 46,868,687 shares of common stock at $2.75 each. Additionally, pre-funded warrants for 25,858,586 shares are priced at $2.749 each. The gross proceeds are expected to be around $200 million before underwriting discounts. The offering will close on or about May 30, 2025. Jefferies, BofA Securities, Piper Sandler, and Barclays serve as joint book-running managers.
# Taysha Gene Therapies Moves Forward with TSHA-102 for Rett Syndrome
## Contact Information for Prospectus
Prospectus requests can be directed to several financial institutions:
– **Jefferies LLC**:
– Address: 520 Madison Avenue, New York, NY 10022
– Phone: (877) 821-7388
– Email: [email protected]
– **BofA Securities, Inc.**:
– Address: 201 North Tryon Street, NC1-022-02-25 Charlotte, NC 28255
– Email: [email protected]
– **Piper Sandler & Co.**:
– Address: 800 Nicollet Mall, J12S03, Minneapolis, MN 55402
– Phone: (800) 747-3924
– Email: [email protected]
– **Barclays Capital Inc.**:
– Address: 1155 Long Island Avenue, Edgewood, NY 11717
– Phone: (888) 603-5847
– Email: [email protected]
## Securities Disclaimer
This press release does not offer to sell or solicit an offer to buy the securities discussed. There will be no sale in jurisdictions where such offers would be illegal before proper registration or qualification.
## About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology firm focused on adeno-associated virus (AAV)-based gene therapies targeting severe monogenic diseases affecting the central nervous system. Its leading product, TSHA-102, is under development for Rett syndrome, a rare disorder without approved treatments targeting its genetic cause. Taysha aims to fulfill significant unmet medical needs and improve patient and caregiver lives. The company’s management boasts extensive experience in gene therapy development and effective commercialization. Taysha utilizes a clinically validated AAV9 capsid and robust manufacturing processes to expedite treatment availability.
## Forward-Looking Statements
This press release includes forward-looking statements under the Private Securities Litigation Reform Act of 1995. Terms like “anticipates,” “believes,” and “expects” denote these statements, which express expectations about TSHA-102 and other candidates’ potential impact on patients. Such statements also address Taysha’s research and anticipated public offering details, which are subject to market risks. Actual results may differ from those projected. For further risks, consult Taysha’s SEC filings, including its Annual report on Form 10-K and Quarterly report on Form 10-Q, available at www.sec.gov. Taysha does not undertake obligations to update forward-looking statements unless required by law.
## Company Contact
– **Hayleigh Collins**
Senior Director, Corporate Communications and Investor Relations
Taysha Gene Therapies, Inc.
Email: [email protected]
## Media Contact
– **Carolyn Hawley**
Inizio Evoke
Email: [email protected]
**Disclaimer**: The opinions expressed in this article do not necessarily reflect those of Nasdaq, Inc.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
